§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US4140851A Expired / Lapsed US ⏱️ 0.0 years remaining

Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides

Assignee: United States Department of Health and Human Services
•
Filing: 1977-11-21
•
Granted: 1979-02-20
•
Expires: 1997-11-21
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Certain trisubstituted pyrrolopyrimidine nucleosides are prepared from toyocamycin and have shown antitumor activity against L1210 and P388 murine leukemia. The particular compounds of interest are selected from the following structural formula: <IMAGE> where X is halo Y is halo; -NH2; -SH, -SR (where R is lower alkyl, benzyl); -OR (where OR is methoxy or alkoxy or where alk is C1-C6); amino (where the amino is -NH2, -alkyl amino or -dialkyl amino and alkyl is C1-C6); gamma gamma dimethyl allyl amino; benzyl amino; phenyl amino; seleno Z is CN; CXNH2 where X is =0, =S, or =Se, =NH, =NHNH2, =NOH. OR Z is = -CH2NH2, -COR=NH Rib= beta -D-ribofuranosyl Preferred members of this group of compounds are shown by the following structural formula: <IMAGE> where X is Cl Y is Cl or NH2 Z is CN, CONH2, or C=NOH-NH2 These compounds are further identified as NSC #145387 (Compound 5) <IMAGE> NSC #177369 (Compound 6) <IMAGE> NSC #182864 (Compound 8) <IMAGE> NSC #180526 (Compound 10) <IMAGE> These compounds at dosages of 13 - 200 mg/kg of body weight administered every other day on the standard six-day schedule showed activity against both L1210 and P388 murine leukemia (Protocol 11, National Institutes of Health, November 11, 1972).

Inventors

  • 👤 Leroy B. Townsend

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-30 23:22
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/14

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 96 words
A pyrrolopyrimidine compound represented by the following structural formula: ##STR14## where X is halo Y is halo; --NH 2 ; --SH, --SR (where R is lower alkyl, benzyl); --OR (where OR is methoxy or alkoxy or where alk is Cl-C6); amino (where the amino is --NH 2 , -alkyl amino or -dialkyl amino and alkyl is C1-C6); gamma gamma dimethyl allyl amino; benzyl amino; phenyl amino; seleno Z is CN; CXNH 2 where X is ═0, ═S, or ═Se, ═NH, ═NHNH 2 , ═NOH or Z is --CH 2 NH 2 , --COR═NH Rib is B-D-ribofuranosyl.
Claim 2
Dependent Claim 96 words
A pyrrolopyrimidine compound represented by the following structural formula: ##STR14## where X is halo Y is halo; --NH 2 ; --SH, --SR (where R is lower alkyl, benzyl); --OR (where OR is methoxy or alkoxy or where alk is Cl-C6); amino (where the amino is --NH 2 , -alkyl amino or -dialkyl amino and alkyl is C1-C6); gamma gamma dimethyl allyl amino; benzyl amino; phenyl amino; seleno Z is CN; CXNH 2 where X is ═0, ═S, or ═Se, ═NH, ═NHNH 2 , ═NOH or Z is --CH 2 NH 2 , --COR═NH Rib is B-D-ribofuranosyl.
Claim 3
Dependent Claim 18 words
A pyrrolopyrimidine compound selected from the group consisting of (a) 5-cyano-2,4-dichloro-7-(-2,3,5-tri-O-acetyl-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine, (b) 4-amino-2-chloro-5-cyano-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine, (c) 4-amino-2-chloro-7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine-5-carboxamide, and (d) 4-amino-2-chloro-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine-5-carboxamidoxime.
Claim 4
Dependent Claim 18 words
A pyrrolopyrimidine compound selected from the group consisting of (a) 5-cyano-2,4-dichloro-7-(-2,3,5-tri-O-acetyl-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine, (b) 4-amino-2-chloro-5-cyano-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine, (c) 4-amino-2-chloro-7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine-5-carboxamide, and (d) 4-amino-2-chloro-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine-5-carboxamidoxime.
Claim 5
Dependent Claim 11 words
The compound according to claim 2 wherein said compound is 5-cyano-2,4-dichloro-7-(-2,3,5-tri-O-acetyl-β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine.
Claim 6
Dependent Claim 11 words
The compound according to claim 2 wherein said compound is 4-amino-2-chloro-5-cyano-7-(β-D-ribofuranosyl)-pyrrolo[2,3-d]pyrimidine.
Claim 7
Dependent Claim 11 words
The compound according to claim 2 wherein said compound is 4-amino-2-chloro-7-(β-D-ribofuranosyl)pyrrolo-[2,3-d]pyrimidine-5-carboxamide.
Claim 8
Dependent Claim 11 words
The compound according to claim 2 wherein said compound is 4-amino-2-chloro-7-(β-D-ribofuranosyl)pyrrolo-[2,3-d]pyrimidine-5-carboxamidoxime.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-02-19 1982-08-21 1983-02-20 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-02-19 1986-08-21 1987-02-20 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-02-19 1990-08-21 1991-02-20 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag